SUPAC Modernization Comment Reopening — Why the Risk-Based Change Classification…

Regulatory Event

Today, July 13, 2026, is the last day of a reopened public comment window on Docket FDA-2026-N-0809, FDA’s Request for Information (RFI) on modernizing the Scale-Up and Postapproval Changes (SUPAC) guidance series — the risk-based framework nearly every CMC program in the country has used, without necessarily thinking about its age, to classify a manufacturing change as major, moderate, or minor under 21 CFR 314.70. The Center for Drug Evaluation and Research’s (CDER) Office of Pharmaceutical Quality opened the original 90-day window on March 3, 2026 (91 FR 10397), closed it June 1, and then reopened it for an additional 30 days by notice on June 11 (91 FR 35483) after industry asked for more time to develop meaningful comments. If you are reading this before midnight Eastern tonight, you still have a narrow, same-day opportunity to add a comment to the docket, which already carries 23 submissions from the original window. If you are reading this after today, the formal reopened window has closed, but that does not end the opportunity: FDA guidance-related dockets generally remain open to comment at any time under 21 CFR 10.115(g)(5), and a comment filed now can still be framed as responsive to the Agency’s stated intent to consider revising this guidance series, even outside the active-consideration window that closes tonight.

The substance of this RFI matters more than its procedural timing. SUPAC-IR (1995), SUPAC-SS (1997), SUPAC-MR (1997), and SUPAC-MEA (1995, updated 2014) were finalized before the 1997 Food and Drug Administration Modernization Act (FDAMA) amendment that codified their risk-based logic into section 506A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 356a), and well before ICH Q9(R1) Quality Risk Management and ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management existed as harmonized standards. FDA’s own notice acknowledges the tension directly: ICH Q12’s established-conditions framework and its post-approval change management protocols are “intended to enhance industry’s ability to manage many CMC changes with greater efficiency and less regulatory oversight prior to implementation,” and FDA states plainly that some SUPAC recommendations may now be superseded by, or may conflict with, these newer guidances. That is a significant admission from the agency that originated the major/moderate/minor classification scheme in the first place, and it is the reason this RFI deserves a substantive comment rather than being treated as routine agency housekeeping.

What the Record Documents

FDA’s four questions are where the real content leverage sits, and each rewards a specific, evidence-based answer rather than a general endorsement or general complaint. First, FDA is asking which SUPAC sections remain genuinely load-bearing — sections your quality system still cites directly to classify a component, composition, equipment, scale, or site change, and which risk-based principles from SUPAC get used for purposes beyond CMC change classification itself. Second, FDA wants specifics on where the guidance is hard to apply: where a change genuinely does not classify cleanly as major, moderate, or minor under the current text, and where the four separate SUPAC documents create overlap or inconsistency with each other or with other FDA CMC guidance. Third, FDA has explicitly floated consolidating the four dosage-form-specific SUPAC guidances into a single document, and separately asked whether recommendations from the draft “Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs” guidance (87 FR 64230) should be incorporated to reduce burden — both concrete, answerable questions rather than open-ended prompts. Fourth, FDA is soliciting new topics altogether, which is the rare opening to propose something SUPAC has never addressed, rather than only revise what exists.

Industry should push back — carefully and with data — on any implicit assumption that ICH Q12 adoption has already reduced the practical need for SUPAC’s own risk classification logic. Establishing a Post-Approval Change Management Protocol (PACMP) or documenting established conditions under Q12 does not, on its own, eliminate the section 506A supplement-classification requirement for a given change; the two frameworks operate together, and a comment that simply asks FDA to “defer entirely to Q12” without addressing how 21 CFR 314.70’s major/moderate/minor reporting categories would then be satisfied is unlikely to move the Agency’s thinking. A stronger comment identifies precisely which SUPAC provisions become redundant once a PACMP or established-conditions strategy is in place for a specific change type, with a proposed alternative classification approach FDA reviewers can evaluate against real submission data — not a request to simply retire risk-based classification as a concept, since risk-based has never meant less rigorous, only proportionate to demonstrated product and process understanding. This distinction matters most for sponsors managing large legacy portfolios approved under pre-Q12 CMC strategies, where the temptation is to assume a newly adopted Q12 lifecycle management approach retroactively simplifies every pending or future SUPAC-classified change; FDA’s own notice gives no indication that is the intended reading, and a comment letter that asks FDA to confirm or clarify the transition expectation for legacy applications would address a real, currently unanswered operational question.

Technical and Quality Context

One area worth explicit support rather than only critique: FDA’s willingness to consider consolidating four aging, dosage-form-specific documents into a single, internally consistent guidance is a genuine simplification opportunity, and industry comment supporting consolidation — provided it preserves the dosage-form-specific technical content that is still valid, particularly SUPAC-MR’s modified-release dissolution and bioequivalence documentation recommendations and SUPAC-SS’s in vitro release testing provisions for nonsterile semisolid products — strengthens FDA’s hand in prioritizing this modernization against competing guidance-development priorities. It is also worth noting that SUPAC-MEA, the manufacturing equipment addendum, was already updated once, in 2014, which suggests FDA is capable of incremental refresh short of a full four-document consolidation if industry comment indicates that narrower path is preferable for a given dosage form category.

THE XGENE SUPAC MODERNIZATION COMMENT ARCHITECTURE 1. Impact Assessment — inventory which SUPAC-IR, SUPAC-SS, SUPAC-MR, and SUPAC-MEA provisions your change control system still cites directly, versus provisions effectively superseded in practice by your ICH Q12 established-conditions strategy. 2. Comment Letter Architecture — respond to FDA’s four numbered questions individually, with section-specific citations, rather than submitting a general commentary on SUPAC’s continued relevance. 3. CMC Gap Analysis — identify where your own major/moderate/minor change classifications have required interpretive judgment calls SUPAC’s current text does not resolve, and document the pattern with real examples. 4. FDA Pre-Comment Engagement — where feasible, raise SUPAC/Q12 interpretive conflicts at a Type C or scientific advice meeting in parallel with any docket comment, since a written comment and a direct CMC review-division conversation reinforce each other.

Decision Relevance

Whether or not your organization gets a comment into today’s reopened window, the underlying question FDA is asking — is your quality system still using SUPAC’s 1990s risk classification logic as written, or has it quietly been supplemented by ICH Q9(R1) and Q12 practice without anyone updating the documented rationale — is worth answering internally regardless of the docket deadline. That is the CMC change-management gap XGene Consulting helps quality and regulatory teams close.